

Maddalena Sansovini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6080079/publications.pdf>

Version: 2024-02-01

34
papers

2,131
citations

361413

20
h-index

377865

34
g-index

37
all docs

37
docs citations

37
times ranked

2017
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. <i>European Journal of Cancer</i> , 2022, 162, 221-236.	2.8	22
2	Theranostic in neuroendocrine tumors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 65, .	0.7	2
3	Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis. <i>Cancers</i> , 2022, 14, 3231.	3.7	5
4	¹⁷⁷ Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 152-160.	6.4	20
5	Combined use of ¹⁷⁷ Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3260-3267.	6.4	29
6	Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis. <i>Pharmaceuticals</i> , 2021, 14, 476.	3.8	16
7	Circulating androgen receptor gene amplification and resistance to ¹⁷⁷ Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. <i>British Journal of Cancer</i> , 2021, 125, 1226-1232.	6.4	13
8	Dosimetry and safety of ¹⁷⁷ Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3008-3017.	6.4	37
9	A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	8
10	Investigation of receptor radionuclide therapy with ¹⁷⁷ Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 923-930.	6.4	56
11	Management of Pancreatic and Duodenal Neuroendocrine Tumors. <i>Updates in Surgery Series</i> , 2018, , 153-167.	0.1	0
12	Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1777-1778.	6.4	1
13	Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with ¹⁷⁷ Lu-D OTATATE. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 490-499.	6.4	95
14	Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 551-557.	2.0	37
15	Peptide receptor radionuclide therapy with ¹⁷⁷ Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and ¹⁸ F-FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1040-1046.	6.4	77
16	Development of sentinel node localization and ROLL in breast cancer in Europe. <i>Clinical and Translational Imaging</i> , 2015, 3, 171-178.	2.1	2
17	Feasibility and utility of re-treatment with ¹⁷⁷ Lu-DOTATATE in GEP-NENs relapsed after treatment with ⁹⁰ Y-DOTATOC. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1955-1963.	6.4	62
18	⁶⁸ Gaâ€‹Dâ€‹TAâ€‹Tâ€‹yr ³ octreotide (â€‹DOTATOCâ€‹) positron emission tomography (â€‹PETâ€‹)/â€‹CTâ€‹ in five cases of ectopic adrenocorticotropinâ€‹secreting tumours. <i>Clinical Endocrinology</i> , 2014, 81, 152-153.	2.4	11

#	ARTICLE	IF	CITATIONS
19	177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1845-1851.	6.4	103
20	Treatment with the Radiolabelled Somatostatin Analog ^{177}Lu -DOTATATE for Advanced Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2013, 97, 347-354.	2.5	104
21	Role of 18FDG PET/CT in patients treated with ^{177}Lu -DOTATATE for advanced differentiated neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 881-888.	6.4	123
22	A case of metachronous double primary neuroendocrine cancer in pancreas/ileum and uterine cervix. <i>Uppsala Journal of Medical Sciences</i> , 2012, 117, 453-456.	0.9	4
23	Peptide Receptor Radionuclide Therapy (PRRT) with ^{177}Lu -DOTATATE in Individuals with Neck or Mediastinal Paraganglioma (PGL). <i>Hormone and Metabolic Research</i> , 2012, 44, 411-414.	1.5	71
24	The Effects of Aging on Testicular Volume and Glucose Metabolism: an Investigation with Ultrasonography and FDG-PET. <i>Molecular Imaging and Biology</i> , 2011, 13, 391-398.	2.6	34
25	Peptide receptor radionuclide therapy with ^{177}Lu -DOTATATE: the IEO phase I-II study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 2125-2135.	6.4	349
26	Peptide Receptor Radionuclide Therapy in a Case of Multiple Spinal Canal and Cranial Paragangliomas. <i>Journal of Clinical Oncology</i> , 2011, 29, e171-e174.	1.6	19
27	Radiolabeling optimization and reduced staff radiation exposure for high-dose ^{90}Y -ibritumomab tiuxetan (HD-Zevalin). <i>Nuclear Medicine and Biology</i> , 2010, 37, 85-93.	0.6	9
28	The Role of Dosimetry in the High Activity ^{90}Y -ibritumomab Tiuxetan Regimens: Two Cases of Abnormal Biodistribution. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 271-275.	1.0	17
29	Peptide receptor radionuclide therapy with ^{90}Y -DOTATOC in recurrent meningioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1407-1416.	6.4	121
30	Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with ^{177}Lu -DOTATATE and ^{90}Y -DOTATOC. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 659-665.	1.0	33
31	Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with ^{90}Y -DOTATOC and ^{177}Lu -DOTATATE: the role of associated risk factors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1847-1856.	6.4	353
32	Age-Related Structural and Metabolic Changes in the Pelvic Reproductive End Organs. <i>Seminars in Nuclear Medicine</i> , 2007, 37, 173-184.	4.6	61
33	Transvaginal evisceration after hysterectomy: Is vaginal cuff closure associated with a reduced risk?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2006, 125, 134-138.	1.1	130
34	^{18}F -FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. <i>European Journal of Surgical Oncology</i> , 2005, 31, 792-797.	1.0	98